Skip to site content

U.S. Department of Health and Human Services

National Pharmacy & Therapeutics Committee

2021

FDA Updates Emergency Use Authorization (EUA) for Janssen COVID-19 Vaccine: Addresses risks of Thrombosis with Thrombocytopenia Syndrome (TTS)

FDA warns that getting alcohol-based hand sanitizer in the eyes can cause serious injury

Seasonal Influenza Vaccine Safety: Reporting Adverse Vaccine Events to the Vaccine Adverse Event Reporting System (VAERS)

FDA requires warnings about increased risk of serious heart-related events, cancer, blood clots, and death for JAK inhibitors that treat certain chronic inflammatory conditions

Reports of Severe Illness Associated with Use of Products Containing Ivermectin to Prevent or Treat COVID-19

FDA Requests the Removal of Pregnancy as a Contraindication Against using Stains

Revised Fact Sheets: FDA Warns of Increased Risk of Guillain-Barré Syndrome Following Janssen COVID-19 Vaccine

Revised Fact Sheets: FDA Warns of Increased Risk of Myocarditis and Pericarditis after Pfizer and Moderna Vaccines

Vaccine Safety: Anaphylaxis and COVID-19 Vaccinations

One Vial of Bamlanivimab Must Be Combined with Two Vials of Etesevimab for Infusion

Tofacitinib (Xeljanz®) May Increase Risk of Serious Heart-Related Problems and Cancer

Abuse and Misuse of Propylhexedrine Nasal Decongestant Causes Serious Harm

Rare and Serious Adverse Vaccine Events Potentially Associated with the Johnson & Johnson/Janssen COVID-19 Vaccine

Pause Lifted on Johnson & Johnson COVID-19 Vaccine Use

Myocarditis & Pericarditis Following mRNA COVID-19 Vaccination

Adverse Events from Alcohol-Based Hand Sanitizers

FDA Restricts Use of Ocaliva® in Some Primary Biliary Cholangitis (PBC) Patients

Scroll To Top